DGS Capital Management LLC Purchases New Stake in Bausch Health Companies Inc. (NYSE:BHC)

DGS Capital Management LLC acquired a new position in shares of Bausch Health Companies Inc. (NYSE:BHC) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 17,745 shares of the company’s stock, valued at approximately $143,000.

Several other large investors have also recently bought and sold shares of the business. SG Americas Securities LLC boosted its position in shares of Bausch Health Companies by 62.0% during the 4th quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company’s stock worth $26,614,000 after purchasing an additional 1,263,706 shares in the last quarter. Merit Financial Group LLC acquired a new stake in shares of Bausch Health Companies in the fourth quarter valued at about $228,000. Sanders Morris Harris LLC boosted its holdings in Bausch Health Companies by 16.0% during the fourth quarter. Sanders Morris Harris LLC now owns 28,975 shares of the company’s stock worth $234,000 after buying an additional 4,000 shares in the last quarter. Range Financial Group LLC acquired a new position in Bausch Health Companies during the fourth quarter worth about $1,004,000. Finally, Geode Capital Management LLC increased its holdings in Bausch Health Companies by 20.5% in the third quarter. Geode Capital Management LLC now owns 636,082 shares of the company’s stock valued at $6,448,000 after buying an additional 108,269 shares in the last quarter. Hedge funds and other institutional investors own 78.65% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on BHC. Royal Bank of Canada boosted their price target on Bausch Health Companies from $10.00 to $11.00 and gave the stock a “sector perform” rating in a research note on Friday, November 1st. Evercore ISI upgraded Bausch Health Companies to a “hold” rating in a research report on Tuesday, October 15th. Finally, StockNews.com upgraded Bausch Health Companies from a “hold” rating to a “buy” rating in a research report on Friday, October 25th. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $7.75.

Bausch Health Companies Stock Down 1.1 %

Shares of NYSE:BHC opened at $7.73 on Monday. The company has a market capitalization of $2.79 billion, a P/E ratio of -16.09 and a beta of 0.69. Bausch Health Companies Inc. has a 52-week low of $3.96 and a 52-week high of $11.46. The stock’s fifty day simple moving average is $7.83 and its 200-day simple moving average is $7.46.

Bausch Health Companies (NYSE:BHC) last released its earnings results on Wednesday, October 30th. The company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.10. The company had revenue of $2.51 billion for the quarter, compared to analyst estimates of $2.42 billion. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. The firm’s quarterly revenue was up 12.2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.03 EPS. On average, sell-side analysts anticipate that Bausch Health Companies Inc. will post 3.73 earnings per share for the current year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.